Hidden Dragon Spreads Its Scales, Dancing in the Courtyard: Full Agenda and Innovations Unveiled at the 2024 VBEF Future Healthcare Innovation Roadshow

Full Company Name:Shanghai Meijie Medical Technology Co., Ltd.

Roadshow Project Name:Multimodal Tumor Therapy System

Roadshow Project Overview:

Shanghai Meijie Medical Technology Co., Ltd. was founded by an innovative team from Shanghai Jiao Tong University. Leveraging its independently developed multimodal thermophysical ablation and immunotherapy technologies over many years, the company is deeply engaged in the field of oncology treatment, committed to leading the development of innovative cancer therapies.

The world’s first multimodal tumor treatment system, developed on this technology platform, integrates liquid nitrogen cryoablation with radiofrequency hyperthermia. By pre-freezing the target lesion and subsequently applying precisely controlled radiofrequency heating, the system achieves effective in situ destruction of tumor cells, enabling local radical cure of solid tumors while simultaneously stimulating the body’s immune response. The system has passed the National Medical Products Administration’s Special Review Procedure for Innovative Medical Devices and has been successfully approved for market launch, bringing a breakthrough transformation to the treatment of solid tumors.

Full Company Name:Guangzhou Qiaojie Li Medical Technology Co., Ltd.

Roadshow Project Name:Internationally Leading Endoscope-Compatible Fully Flexible Dual-Arm Surgical Robot

Roadshow Project Overview:

Founded in 2021, Qiaojie Li is a medical technology company incubated by The University of Hong Kong, dedicated to the research and development of a globally leading, fully flexible endoscopic surgical robot system. This system is compatible with existing hospital endoscopy equipment, enhances surgical efficiency, seamlessly integrates into current surgical workflows, and significantly optimizes the learning curve for endoscopic procedures.

The project has now secured over $17 million in financing, which will be used to further R&D and clinical registration. The company’s long-term goal is to develop a new generation of minimally invasive surgical robots that assist physicians in performing minimally invasive procedures while conducting endoscopic examinations through the body’s natural orifices.

Full Company Name:Gaowei Medicine (Hangzhou) Co., Ltd.

Roadshow Project Name:High-Dimensional Biology and AI-Driven Drug Design Empower the Drug Target Discovery Platform

Roadshow Project Overview:

GaoWei Medicine is a startup founded by Professor Li Xu of Westlake University. Established in 2022, the company is dedicated to building a world-leading drug discovery platform based on high-dimensional biology. In the early stages of drug development, we integrate big data from our proprietary protein networks, high-throughput drug screening, CRISPR screening, and patient cohorts using high-dimensional biological analysis. This allows us to create “profiles” of factors associated with complex diseases within a high-dimensional pathological space, thereby rapidly and precisely identifying novel intervention points for various refractory diseases or undruggable targets. GaoWei Medicine’s angel round was led by Beta Pharma and Westlake Innovation Investment, and the company is currently raising its Pre-A round.

Enterprise Full Name:Shanghai Huicheng Scientific and Educational Instruments Co., Ltd.

Roadshow Project Name:Pain Points in Traditional Healthcare and Systematic Digital-Intelligence Solutions

Roadshow Project Overview:

Changes in the Centralized Drug Procurement Policy in the Pharmaceutical Industry,

Intensified Homogenized Competition in the Pharmaceutical and Healthcare Industry,

Healthcare hotspots offer few highlights, while investment risks surge dramatically,

Shanghai Huicheng Medical Health Innovation Digital Intelligence Product System,

Help you break free from zero-sum competition and embrace growth-driven innovation,

Shanghai Huicheng’s Digital Intelligence Healthcare Innovation Application System Is Sure to Impress

Shanghai Huicheng’s Three Core Technologies: AI Brain-Inspired Intelligent Sensing for Real-Time Monitoring, Proprietary Functional Audio Stimulation with Independent Intellectual Property Rights, and Long-Term Continuous Data Analysis and Follow-Up

The “Multi-Fast, Good, Economical, Easy, and Comprehensive” product system serves individuals across all age groups—including children, young and middle-aged adults, the elderly—as well as special populations. It provides preventive, healthcare, regulatory, and rehabilitative services addressing psychological, behavioral, health, and disease-related issues, covering nearly all general hospital departments and scenarios spanning pre-hospital, in-hospital, and post-hospital care.

Enterprise Full Name:Westlake Biopharmaceutical Technology (Hangzhou) Co., Ltd.

Roadshow Project Name:Development of Red Blood Cell–Antibody Conjugates for the Treatment of Immunotherapy-Resistant Cancers

Roadshow Project Overview:

By engineering mature red blood cells or stem cell-derived red blood cells, the company has pioneered REDx, a third-generation, highly efficient, and non-invasive red blood cell therapy technology. It has developed multiple First-in-Class red blood cell-based therapeutics targeting major diseases such as cancer, immune disorders, and metabolic conditions. Currently, the company’s lead candidate, WTX-212, has received ethical approval from multiple clinical trial committees and is undergoing clinical trials in collaboration with several Grade A tertiary hospitals, including The First Affiliated Hospital of Zhejiang University School of Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Provincial People’s Hospital, and Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine. Clinical studies have demonstrated that WTX-212 exhibits robust anti-tumor efficacy and a favorable safety profile. For patients with various solid tumors and hematologic malignancies who have exhausted standard treatment options, this product offers a novel and promising cellular therapeutic option capable of treating malignant tumors unresponsive to immunotherapies, thereby addressing a significant unmet clinical need.

Full Company Name:Beijing Yiyue Technology Co., Ltd.

Roadshow Project Name:Multimodal Radar 3D Visual Assessment, Training, and Rehabilitation System

Roadshow Project Brief:

Yiyue Technology’s core product, “Shukangshi,” is an innovative medical device that integrates high-precision AI-based motion assessment, big data-driven prescription, and quantified rehabilitation training. As part of the National Key R&D Program, and specifically as a translational outcome of projects related to the Winter Olympics, Shukangshi underwent clinical validation in over 4,800 cases through collaborative research with the Department of Sports Medicine at Peking University Third Hospital. This validation confirmed its effectiveness in digitizing rehabilitation protocols for both surgical and conservative treatments in sports medicine. Leveraging a high-precision algorithm for assessing joint motion characteristics developed in collaboration with the CAD&CG Laboratory at Zhejiang University, Shukangshi achieves an assessment accuracy as high as 0.6%, outperforming similar domestic products. Currently, Shukangshi has been widely adopted in the orthopedics, sports medicine, and rehabilitation departments of more than one hundred hospitals across China. The company holds 21 intellectual property rights and was awarded the Silver Prize at the 17th Beijing Invention and Innovation Competition.

Full Company Name:GeneOnline & BioDND—Life Health and Medical Technology Global Expansion Service Platform

Roadshow Project Name:GeneOnline & BioDND—A Service Platform for Life, Health, and Medical Technology Going Global

Roadshow Project Brief:

GeneOnline is a B2B professional information company specializing in the biotechnology industry, providing the life sciences sector with the professional and independent brand channel GeneOnline and the business development database BIODND. Founded in Taipei in 2015, the company expanded its headquarters to North America in 2019. GeneOnline has become Asia’s most influential platform for biopharmaceutical information exchange, serving as the preferred channel for marketing exposure for major global pharmaceutical companies, biotech firms, and academic medical institutions. BIODND, a biomedical industry analysis and matchmaking platform, hosts the most comprehensive biopharmaceutical database in the Asia-Pacific region. By integrating AI models, it proactively analyzes and forecasts industry trends and investment directions in life sciences-related fields, mapping industrial supply chains and staying ahead of market developments.

Full Company Name:Jiali Medical Technology (Guangzhou) Co., Ltd.

Roadshow Project Name:Novel Immunotherapy for Advanced Gastrointestinal Cancer

Roadshow Project Overview:

Due to the limited availability and suboptimal efficacy of current therapies, mortality rates for gastrointestinal (GI) cancers remain high, creating an urgent need for breakthrough treatments to break this deadlock. ARB202 is a first-in-class bispecific antibody developed by Aibelle Pharmaceuticals, the parent company of Jiali, targeting the GI antigen CDH17 and T-cell CD3 based on its unique and innovative CDH17 target platform. ARB202 features a differentiated structure with distinct affinities for anti-CDH17 and anti-CD3, which ensures high specificity and potent cytotoxic activity while avoiding the risk of systemic immune reactions caused by excessive T-cell activation. Consequently, it demonstrates favorable safety, pharmacokinetic profiles, and developability. Preclinical study results show that ARB202 effectively enhances the interaction between T cells and CDH17-expressing GI tumor cell lines, leading to T-cell activation and IL-2 release, thereby effectively inducing tumor cell killing. In vivo administration of low doses of the ARB202 antibody can effectively inhibit tumor growth. Currently, Phase I clinical trials of ARB202 are underway in Australia and China (Hong Kong) for the indication of advanced malignant gastrointestinal tumors. Core competitive advantages of the project include: (1) The team possesses extensive experience in drug development and commercialization; (2) Highly differentiated target selection and a clear mechanism of action; (3) A patent barrier has been established around the CDH17 target; (4) High feasibility of targeting CDH17 as a novel therapeutic approach for digestive tract tumors; (5) Highly recognized by international biotechnology companies and investment institutions.

Full Company Name:Zhongke Huisheng (Beijing) Pharmaceutical Technology Co., Ltd.

Roadshow Project Name:Applications of the Nanopump Technology Platform in Drug Delivery

Roadshow Project Overview:

Zhongke Huisheng (Beijing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Zhongke Huisheng”) is an innovative formulation R&D enterprise jointly founded by Wei Shifeng’s team—experts in high-end drug carrier technology and industrialization of advanced formulations from the Institute of Process Engineering, Chinese Academy of Sciences—and Weilai Capital. The company’s core technology, Nano-Pump drug carrier technology, has passed pilot-scale and industrialization validation. This technology is not only applicable to a wide range of drug molecules and disease areas but also addresses challenges in drug delivery, such as lymphatic tracing, tissue labeling, oral administration of macromolecular biologics, short half-life, and narrow therapeutic window, providing effective solutions to industry-wide problems. It features high technical barriers, broad applicability, and strong feasibility. Meanwhile, the company focuses on developing sustained-release and intelligent controlled-release formulations across multiple therapeutic areas and has accumulated extensive experience in the research and development of functional materials.

Full Company Name:Nantong Zhenle Pharmaceutical Technology Co., Ltd.

Roadshow Project Name:Innovative Drugs Focused on Advanced Drug Delivery Systems

Roadshow Project Overview:

Zhenle Pharma, founded in 2018 by Professor Zhen Gu, a leading scholar in pharmaceutical formulation, is committed to becoming a global leader in novel intelligent drug delivery. Leveraging its exclusive global patents and internationally advanced novel formulation technologies, the company actively conducts R&D on new drug formulations, represented by platelet-targeted drug delivery systems, intelligent microneedle transdermal delivery systems, and nucleic acid delivery systems. Zhenle’s innovative drug delivery systems break the limitations of traditional oral and injectable formulations, providing patients with better therapeutic outcomes while placing greater emphasis on medication experience and reducing patient suffering. Backed by a professional R&D team and a world-class advisory team (including Dr. Robert Langer, MIT Professor and co-founder of Moderna), Zhenle has developed formulation products loaded with various small-molecule and large-molecule drugs (including cytokines, antibodies, and vaccines). To date, the company has achieved a series of breakthroughs, among which its “platelet-targeted drug delivery system” is a global first.